E
Eckart Schott
Researcher at Charité
Publications - 125
Citations - 5711
Eckart Schott is an academic researcher from Charité. The author has contributed to research in topics: Hepatitis C & Hepatocellular carcinoma. The author has an hindex of 36, co-authored 121 publications receiving 4666 citations. Previous affiliations of Eckart Schott include Harvard University & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration
Sabrina M. Lehmann,Christina Krüger,Boyoun Park,Katja Derkow,Karen Rosenberger,Jan Baumgart,Thorsten Trimbuch,Gina D. Eom,Michael Hinz,David Kaul,Piet Habbel,Roland E. Kälin,Eleonora Franzoni,Agnieszka Rybak,Duong T. T. Nguyen,Rüdiger W. Veh,Olaf Ninnemann,Oliver Peters,Robert Nitsch,Frank L. Heppner,Douglas T. Golenbock,Eckart Schott,Hidde L. Ploegh,F. Gregory Wulczyn,Seija Lehnardt +24 more
TL;DR: The results suggest that microRNAs can function as signaling molecules and identify TLR7 as an essential element in a pathway that contributes to the spread of CNS damage.
Journal ArticleDOI
Enteric dysbiosis associated with a mouse model of alcoholic liver disease
Arthur W. Yan,Derrick E. Fouts,Johannes Brandl,Johannes Brandl,Peter Stärkel,Manolito Torralba,Eckart Schott,Hide Tsukamoto,Karen E. Nelson,David A. Brenner,Bernd Schnabl +10 more
TL;DR: Alcohol feeding is associated with intestinal bacterial overgrowth and enteric dysbiosis, and intestinal antimicrobial molecules are dysregulated following chronic alcohol feeding contributing to changes in the enteric microbiome and to alcoholic steatohepatitis.
Journal ArticleDOI
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Thomas Yau,Joong-Won Park,Richard S. Finn,A-L Cheng,Philippe Mathurin,Julien Edeline,Masatoshi Kudo,K.-H. Han,James J. Harding,Philippe Merle,Olivier Rosmorduc,L. Wyrwicz,Eckart Schott,S.P. Choo,Robin Katie Kelley,D. Begic,G. Chen,Jaclyn Neely,Jeffrey Anderson,Bruno Sangro +19 more
TL;DR: Though the primary endpoint of OS did not achieve statistical significance vs SOR, NIVO showed clinically meaningful improvements in OS, ORR, and CR rate as 1L treatment for aHCC and demonstrated a favorable safety profile consistent with previous reports.
Journal ArticleDOI
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection
Yves Horsmans,Thomas Berg,Jean-Pierre Desager,Tobias Mueller,Eckart Schott,Simon P. Fletcher,Kevin R. Steffy,Lisa A Bauman,Bradley M. Kerr,Averett Devron R +9 more
TL;DR: Systemic administration of the selective TLR7 agonist isatoribine resulted in dose‐dependent changes in immunologic biomarkers and a statistically significant antiviral effect with relatively few and mild side effects.
Journal ArticleDOI
A Vicious Cycle Involving Release of Heat Shock Protein 60 from Injured Cells and Activation of Toll-Like Receptor 4 Mediates Neurodegeneration in the CNS
Seija Lehnardt,Eckart Schott,Thorsten Trimbuch,Dinah Laubisch,Christina Krueger,Gregory Wulczyn,Robert Nitsch,Joerg R. Weber +7 more
TL;DR: It is shown that the intracellular chaperone heat shock protein 60 (HSP60) serves as a signal of CNS injury by activating microglia through a toll-like receptor 4 (TLR4)-dependent and myeloid differentiation factor 88 (MyD88)-dependent pathway.